Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.77 |
| ▸ | NPC1 | O15118 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.77 |
| ▸ | PKM | P14618 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.58 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.58 |
| ▸ | KRAS | P01116 | 1/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793176 | 1.00 | RAB9A (0.77) | RAB9ANPC1MAPTPKMKDM4E | |
| SCHEMBL12257967 | 0.92 | MAPT (0.90) | RAB9ANPC1MAPTPKMKDM4E | |
| SCHEMBL4400320 | 0.87 | MAPT (1.00) | RAB9ANPC1MAPTPKMKDM4E | |
| SCHEMBL977480 | 0.87 | MAPT (1.00) | RAB9ANPC1MAPTPKMKDM4E | |
| SCHEMBL1604280 | 0.86 | MAPT (0.79) | RAB9ANPC1MAPTPKMKDM4E | |
| SCHEMBL31436352 | 0.86 | MAPT (0.79) | RAB9ANPC1MAPTPKMKDM4E | |
| SCHEMBL16810371 | 0.85 | RAB9A (0.72) | RAB9ANPC1MAPTPKMKDM4E | |
| SCHEMBL1929871 | 0.84 | PKM (0.82) | RAB9ANPC1MAPTPKMKDM4E | |
| SCHEMBL9231011 | 0.84 | MAPT (0.77) | RAB9ANPC1MAPTPKMKDM4E | |
| SCHEMBL657047 | 0.84 | MAPT (0.77) | RAB9ANPC1MAPTPKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1326835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058903-A1 | Benzamide compounds as apo b secretion inhibitors | APOB, APOL1, SCARB1 | RAB9A 3707/4885NPC1 64/4885MAPT 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.